|会社名||Redhill Biopharma Ltd Ramat Gan （レッドヒル・バイオファ―マ）|
|分野（sector）||Health Care ヘルスケア|
|業種||― 医療関連（Health Care）|
|概要||事業概要 -- レッドヒル・バイオファ―マは、イスラエルのバイオ製薬会社。胃腸癌を含む炎症性および胃腸疾患の治療用に、後期の臨床段階にある独自の経口投与薬剤を開発、買収に注力する。イスラエル、米国、カナダ、欧州で事業を展開。同社の製品パイプラインは、後期の臨床段階にある8薬の治療候補で構成される。 RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. It operates through two segments: Commercial Operations and Research & Development. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's U.S. subsidiary. The Research and Development segment includes all activities related to the research and development of therapeutic candidates and is being performed by the Company. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.|
|本社所在地||21 Ha'arba'a Street Tel-Aviv 64739 ISR|
|市場名||NASDAQ Small Cap|
RedHill Biopharma to Discontinue Promotion of Legacy Products 2020/01/21 14:14:42 Investing News Network
RedHill Biopharma is discontining its commercialization agreements for its legacy products and focusing on its lead commercial products. The post RedHill Biopharma to Discontinue Promotion of Legacy Products appeared first on Investing News Network .
RedHill Biopharma Regains Rights to Proprietary Bowel Preparation 2020/01/02 14:18:21 Investing News Network
RedHill Biopharma has terminated a 2014 license agreement, regaining its exclusive rights to a proprietary formulation for bowel preparation. The post RedHill Biopharma Regains Rights to Proprietary Bowel Preparation appeared first on Investing News Network .
US FDA approves RedHill's bacterial infection treatment 2019/11/04 11:50:39 Channel NewsAsia
REUTERS: RedHill Biopharma Ltd's said on Monday its three-drug combination therapy to treat Helicobacter pylori bacterial infections had been approved by the U.S. Food and Drug Administration. The drug, Talicia, is an oral capsule comprising two antibiotics, amoxicillin and rifabutin, as well as …
US FDA approves RedHill's H. pylori infection treatment 2019/11/04 11:25:30 Channel NewsAsia
REUTERS: The U.S. Food and Drug Administration has approved RedHill Biopharma Ltd's drug to treat infections caused by bacteria known as Helicobacter pylori, the Israel-based company said on Monday. RedHill expects to launch the drug, Talicia, in the United States in the first quarter next year …
Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates 2019/11/01 12:05:07 Benzinga
The FDA worked overtime in October , deciding on the fate of several therapies and treatment options. Most reviews produced positive outcomes. Three new molecular entities, or NMEs, were approved in October, taking the total number of NME approvals for the year to 33 compared to 47 approvals by the same time last year. Some notable approvals that came through in the month included Eli Lilly And Co (NYSE: LLY )'s migraine drug Reyvow and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )'s new cystic fibrosis triplet regimen Trikafta in patients with a specific mutation. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is allotted six months to review the drug. These time frames begin on the date that an NDA is accepted by the FDA as complete. Here are the key PDUFA Dates for the upcoming month. Redhill Awaits Nod For Drug To Treat Carcinogenic Bacterial Infection Company: REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Type of Application: NDA Candidate: Talicia, or RHB-105 Indication: H.
関連キーワード （― 米国株 レッドヒル・バイオファ―マ RDHL Redhill Biopharma Ltd.）